Markets US

Wendy's rejected a $1.4 billion takeover offer from Nelson Peltz’s Trian Fund Management, calling the bid substantially undervalued and incompatible with its turnaround strategy.

Wendy's Rejects $1.4 Billion Takeover Bid from Trian

Wendy's board's independent committee dismissed Trian’s $7.35-per-share cash offer, valuing the burger chain at $1.4 billion, as failing to reflect its long-term growth plans. The company disclosed a 7-quarter decline in same-store sales but reported Q3 2026 earnings and revenue that exceeded Wall Street forecasts. Wendy's activated a poison pill to block the bid, a move that has kept its shares down nearly 60% over the past three years. The rejection also came as Wendy's stock fell less than 1% in premarket trading.

The offer, made on October 28, 2026, marked another clash in Wendy's ongoing relationship with Peltz, who has previously pushed for changes in the company’s strategy. While the board emphasized confidence in its turnaround plan, the decision highlights persistent challenges in reversing declining sales. The poison pill, effective through November 2027, will deter further hostile bids unless Trian or other investors find a way to bypass it.

Analysts note the rejection underscores Wendy's commitment to its strategy despite financial headwinds. However, the company’s prolonged sales slump and stock underperformance remain critical risks. Competitors like Dine Brands, which owns Applebee's, may now face similar activist pressures. Trian declined to comment on the decision, leaving the door open for future bids or strategic partnerships.

Wendy's will continue its turnaround efforts without further details on potential deals or shareholder agreements. The company’s ability to stabilize same-store sales and deliver consistent earnings will remain key to its long-term value proposition.

Wendy's poison pill remains active until November 2027. Trian has not commented on the decision. The company will continue its turnaround strategy without additional details on potential bids or shareholder agreements.

Wendy's rejection of Trian's bid signals confidence in its strategy, but declining sales and stock performance highlight ongoing challenges.

Topics: Takeover Bid, Wendy'S, Trian Fund Management, Same-Store Sales, Poison Pill, Share Price, Turnaround Strategy, Activist Investor

#WendyTakeover #TrianBid #PoisonPill #SameStoreSales #StockPerformance #TurnaroundStrategy

Source: CNBC